A 2 mg dose of Abilify (aripiprazole) is appropriate for patients with impaired renal function without dose adjustment.
According to the FDA label, no dosage adjustment for Abilify is required based on renal function, even in patients with severe renal impairment (glomerular filtration rate between 15 and 90 mL/minute). 1
Pharmacokinetic Rationale
The lack of need for dose adjustment is supported by pharmacokinetic data showing:
- Renal clearance of aripiprazole is negligible (0.04 mL/h/kg in healthy controls), indicating minimal renal elimination 2
- Aripiprazole undergoes primarily hepatic metabolism via CYP3A4 and CYP2D6, not renal excretion
- In a dedicated renal impairment study, subjects with severe renal impairment (creatinine clearance <30 mL/min) showed no meaningful differences in aripiprazole pharmacokinetics compared to those with normal renal function 2
- While total Cmax was numerically higher (approximately 40%) in renally impaired subjects, the unbound drug clearance (CL/Fu) remained comparable between groups 2
Clinical Evidence
A case report demonstrated successful use of aripiprazole 30 mg/day in a patient with chronic renal failure comorbid with psychotic anorexia nervosa and epilepsy, with good tolerability and no reported side effects 3. This supports safety even at higher doses in renal impairment.
Important Considerations
Protein binding alterations: Research indicates that plasma protein binding of aripiprazole may be reduced in chronic renal failure patients, particularly in the presence of uremic toxins like indoxyl sulfate 4. However, this does not translate into a need for routine dose adjustment, as the FDA label explicitly states no adjustment is required 1.
Dialysis: Since aripiprazole is highly protein-bound (>99%), dialysis is unlikely to result in significant drug removal 2. No supplemental dosing post-dialysis is necessary.
Dosing Recommendation
For a patient with impaired renal function, initiate aripiprazole at 2 mg as you would in a patient with normal renal function. The standard titration schedule applies:
- Starting doses typically range from 2-5 mg for delirium management 5 or 5-10 mg for schizophrenia 6
- Titrate based on clinical response and tolerability, not renal function
- Monitor for standard aripiprazole adverse effects (headache, agitation, anxiety, insomnia, dizziness, drowsiness) 5
The 2 mg dose is below the typical therapeutic threshold (which appears to be between 5-10 mg/day for schizophrenia 6), but may be appropriate for initial dosing in elderly, frail patients, or for specific indications like delirium where lower starting doses are recommended 5.